Clinical trial
Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma…
NCT00003456 · Burzynski Research Institute, Other · Completed
Key facts
| NCT number | NCT00003456 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme |
| Official title | Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Glioblastoma Multiforme |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme of Brain |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 40 |
| Start date | Mar 14, 1995 |
| Primary completion | Dec 7, 2004 |
| Completion | Dec 7, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 22, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: